David Belada
Impact in
- Pathology and Forensic Medicine top 0.1%
- Lymphoma Diagnosis and Treatment
- Genetics top 1%
- Chronic Lymphocytic Leukemia Research
Papers in
-
- Lymphoma Diagnosis and Treatment 153
- Genetics 21
- Chronic Lymphocytic Leukemia Research 21
- Co-authors
- Marek Trněný (65 shared papers)Andrea Janíková (36 shared papers)Heidi Móciková (42 shared papers)Robert Pytlík (30 shared papers)Vít Procházka (35 shared papers)Lukáš Smolej (19 shared papers)Vít Campr (25 shared papers)Martin Šimkovič (16 shared papers)
- Journals
- Blood (39 papers)Hematological Oncology (22 papers)HemaSphere (7 papers)Journal of Clinical Oncology (7 papers)Annals of Hematology (6 papers)
- Partner nations
- CzechiaUnited StatesFrance
In The Last Decade
David Belada
166 papers receiving 5.3k citations
David Belada's Hit Papers
Peers
Comparison fields: 5 of 73
- Pathology and Forensic Medicine 3.9k
- Genetics 605
- Oncology 356
- Radiology, Nuclear Medicine and Imaging 189
- Neurology 107
Countries citing papers authored by David Belada
This map shows the geographic impact of David Belada's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Belada with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Belada more than expected).
Fields of papers citing papers by David Belada
This network shows the impact of papers produced by David Belada. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Belada. The network helps show where David Belada may publish in the future.
Co-authors
The 25 scholars most cited alongside David Belada, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 187 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial Hit paper breakdown → | 2010 | 844 |
| 2 | Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial Hit paper breakdown → | 2018 | 561 |
| 3 | Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non–Germinal Center B-Cell Diffuse Large B-Cell Lymphoma Hit paper breakdown → | 2019 | 478 |
| 4 | A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study Hit paper breakdown → | 2020 | 368 |
| 5 | Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma Hit paper breakdown → | 2017 | 344 |
| 6 | 2019 | 221 | |
| 7 | ROBUST: A Phase III Study of Lenalidomide Plus R-CHOP Versus Placebo Plus R-CHOP in Previously Untreated Patients With ABC-Type Diffuse Large B-Cell Lymphoma Hit paper breakdown → | 2021 | 204 |
| 8 | The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma Hit paper breakdown → | 2021 | 182 |
| 9 | 2018 | 170 | |
| 10 | Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma Hit paper breakdown → | 2022 | 134 |
| 11 | 2016 | 129 | |
| 12 | 2018 | 103 | |
| 13 | 2018 | 103 | |
| 14 | 2023 | 77 | |
| 15 | 2019 | 74 | |
| 16 | 2013 | 67 | |
| 17 | 2011 | 55 | |
| 18 | 2019 | 51 | |
| 19 | 2017 | 50 | |
| 20 | 2020 | 45 |
About David Belada
David Belada is a scholar working on Pathology and Forensic Medicine, Genetics, Oncology, Dermatology and Neurology, having authored 187 papers that have together received 5.5k indexed citations. Recurring topics across this work include Lymphoma Diagnosis and Treatment (153 papers), Chronic Lymphocytic Leukemia Research (21 papers), CNS Lymphoma Diagnosis and Treatment (5 papers), Cutaneous lymphoproliferative disorders research (4 papers), CAR-T cell therapy research (3 papers), COVID-19 Clinical Research Studies (2 papers), Pancreatic and Hepatic Oncology Research (1 paper) and Cardiac tumors and thrombi (1 paper). The work is most often cited by research in Pathology and Forensic Medicine (3.9k citations), Genetics (605 citations), Oncology (356 citations), Radiology, Nuclear Medicine and Imaging (189 citations) and Neurology (107 citations). David Belada has collaborated with scholars based in Czechia, United States and France. Frequent co-authors include Marek Trněný, Andrea Janíková, Heidi Móciková, Robert Pytlík, Vít Procházka, Lukáš Smolej, Vít Campr, Martin Šimkovič, Павел Зак and Jiří Mayer. Their work appears in journals such as Blood, Hematological Oncology, HemaSphere, Journal of Clinical Oncology and Annals of Hematology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.